The University of California, Davis has launched the Institute for Psychedelics and Neurotherapeutics to advance basic knowledge about the mechanisms of psychedelics.
In a groundbreaking development, Australia is to reclassify psilocybin and MDMA to enable prescribing by authorised psychiatrists.
Researchers at the University of Alabama, Birmingham, say the study findings demonstrate the critical role of the protein Tiam1 in the pathophysiology of chronic pain-induced mood...
Psycheceutical Bioscience has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic...
Diamond Therapeutics has received approval from Health Canada to carry out a Phase 2 low-dose psilocybin trial for the treatment of generalised anxiety disorder (GAD) on...
Small Pharma has reported positive top-line results from its Phase 2a Trial of SPL026 in Major Depressive Disorder (MDD).
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
Cybin has announced key highlights from its study evaluating Kernel’s Flow wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Results from MAPS PBC’s study have demonstrated a biological correlation between a reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders.